221 related articles for article (PubMed ID: 21391610)
21. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and evaluation of highly selective pyridone-based class II MET inhibitors.
She N; Zhuo L; Jiang W; Zhu X; Wang J; Ming Z; Zhao X; Cong X; Huang W
Bioorg Med Chem Lett; 2014 Aug; 24(15):3351-5. PubMed ID: 24951334
[TBL] [Abstract][Full Text] [Related]
23. Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors.
Zhang D; Ai J; Liang Z; Zhu W; Peng X; Chen X; Ji Y; Jiang H; Luo C; Geng M; Liu H
Bioorg Med Chem Lett; 2013 Apr; 23(8):2408-13. PubMed ID: 23474386
[TBL] [Abstract][Full Text] [Related]
24. Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit.
Hu E; Tasker A; White RD; Kunz RK; Human J; Chen N; Bürli R; Hungate R; Novak P; Itano A; Zhang X; Yu V; Nguyen Y; Tudor Y; Plant M; Flynn S; Xu Y; Meagher KL; Whittington DA; Ng GY
J Med Chem; 2008 Jun; 51(11):3065-8. PubMed ID: 18447379
[TBL] [Abstract][Full Text] [Related]
25. Characterization of Itk tyrosine kinase: contribution of noncatalytic domains to enzymatic activity.
Hawkins J; Marcy A
Protein Expr Purif; 2001 Jul; 22(2):211-9. PubMed ID: 11437596
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK).
Trani G; Barker JJ; Bromidge SM; Brookfield FA; Burch JD; Chen Y; Eigenbrot C; Heifetz A; Ismaili MHA; Johnson A; Krülle TM; MacKinnon CH; Maghames R; McEwan PA; Montalbetti CAGN; Ortwine DF; Pérez-Fuertes Y; Vaidya DG; Wang X; Zarrin AA; Pei Z
Bioorg Med Chem Lett; 2014 Dec; 24(24):5818-5823. PubMed ID: 25455497
[TBL] [Abstract][Full Text] [Related]
27. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
[TBL] [Abstract][Full Text] [Related]
28. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
Pan Z; Scheerens H; Li SJ; Schultz BE; Sprengeler PA; Burrill LC; Mendonca RV; Sweeney MD; Scott KC; Grothaus PG; Jeffery DA; Spoerke JM; Honigberg LA; Young PR; Dalrymple SA; Palmer JT
ChemMedChem; 2007 Jan; 2(1):58-61. PubMed ID: 17154430
[No Abstract] [Full Text] [Related]
29. Discovery and SAR of 2-amino-5-[(thiomethyl)aryl]thiazoles as potent and selective Itk inhibitors.
Das J; Liu C; Moquin RV; Lin J; Furch JA; Spergel SH; Doweyko AM; McIntyre KW; Shuster DJ; O'Day KD; Penhallow B; Hung CY; Kanner SB; Lin TA; Dodd JH; Barrish JC; Wityak J
Bioorg Med Chem Lett; 2006 May; 16(9):2411-5. PubMed ID: 16481166
[TBL] [Abstract][Full Text] [Related]
30. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
[TBL] [Abstract][Full Text] [Related]
31. Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors.
Marzaro G; Chilin A; Guiotto A; Uriarte E; Brun P; Castagliuolo I; Tonus F; González-Díaz H
Eur J Med Chem; 2011 Jun; 46(6):2185-92. PubMed ID: 21447431
[TBL] [Abstract][Full Text] [Related]
32. Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.
Han S; Czerwinski RM; Caspers NL; Limburg DC; Ding W; Wang H; Ohren JF; Rajamohan F; McLellan TJ; Unwalla R; Choi C; Parikh MD; Seth N; Edmonds J; Phillips C; Shakya S; Li X; Spaulding V; Hughes S; Cook A; Robinson C; Mathias JP; Navratilova I; Medley QG; Anderson DR; Kurumbail RG; Aulabaugh A
Biochem J; 2014 Jun; 460(2):211-22. PubMed ID: 24593284
[TBL] [Abstract][Full Text] [Related]
33. Structural biology contributions to tyrosine kinase drug discovery.
Cowan-Jacob SW; Möbitz H; Fabbro D
Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of 8-amino-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives as glycogen synthase kinase-3 (GSK-3) inhibitors.
Chun K; Park JS; Lee HC; Kim YH; Ye IH; Kim KJ; Ku IW; Noh MY; Cho GW; Kim H; Kim SH; Kim J
Bioorg Med Chem Lett; 2013 Jul; 23(13):3983-7. PubMed ID: 23683591
[TBL] [Abstract][Full Text] [Related]
35. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
Charrier JD; Durrant SJ; Golec JM; Kay DP; Knegtel RM; MacCormick S; Mortimore M; O'Donnell ME; Pinder JL; Reaper PM; Rutherford AP; Wang PS; Young SC; Pollard JR
J Med Chem; 2011 Apr; 54(7):2320-30. PubMed ID: 21413798
[TBL] [Abstract][Full Text] [Related]
36. Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase.
Cheney IW; Yan S; Appleby T; Walker H; Vo T; Yao N; Hamatake R; Hong Z; Wu JZ
Bioorg Med Chem Lett; 2007 Mar; 17(6):1679-83. PubMed ID: 17251021
[TBL] [Abstract][Full Text] [Related]
37. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.
Verheijen JC; Richard DJ; Curran K; Kaplan J; Lefever M; Nowak P; Malwitz DJ; Brooijmans N; Toral-Barza L; Zhang WG; Lucas J; Hollander I; Ayral-Kaloustian S; Mansour TS; Yu K; Zask A
J Med Chem; 2009 Dec; 52(24):8010-24. PubMed ID: 19894727
[TBL] [Abstract][Full Text] [Related]
38. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
Verkhivker GM
Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
[TBL] [Abstract][Full Text] [Related]
39. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
Leproult E; Barluenga S; Moras D; Wurtz JM; Winssinger N
J Med Chem; 2011 Mar; 54(5):1347-55. PubMed ID: 21322567
[TBL] [Abstract][Full Text] [Related]
40. Itk kinase inhibitors: initial efforts to improve the metabolical stability and the cell activity of the benzimidazole lead.
Moriarty KJ; Winters M; Qiao L; Ryan D; DesJarlis R; Robinson D; Cook BN; Kashem MA; Kaplita PV; Liu LH; Farrell TM; Khine HH; King J; Pullen SS; Roth GP; Magolda R; Takahashi H
Bioorg Med Chem Lett; 2008 Oct; 18(20):5537-40. PubMed ID: 18819794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
